SOUTH SAN FRANCISCO, Calif.,
July 26, 2016 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its second quarter
2016 financial results after market close on Tuesday, August 2, 2016. Rigel senior
management will follow the announcement with a live conference call
and webcast at 5:00pm Eastern Time
(2:00pm Pacific Time) to discuss the
financial results.
Participants can access the live conference call by dialing
855-892-1489 (domestic) or 720-634-2939 (international) and using
the Conference ID number 54498109. The conference call will
also be webcast live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and
available for replay after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc. is a clinical-stage biotechnology company
dedicated to the discovery and development of novel, targeted drugs
in the therapeutic areas of immunology, oncology and
immuno-oncology. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
current clinical programs include fostamatinib, an oral spleen
tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical
trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic
anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy
(IgAN). In addition, Rigel has two oncology product candidates in
Phase 1 development with partners BerGenBio AS and Daiichi
Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2016-financial-results-300303623.html
SOURCE Rigel Pharmaceuticals, Inc.